Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody

mAbs

Volumn 11, Issue 1, 2019, Pages 145-152

  Rehder, Douglas S ^a   Wisniewski, Chris J ^a   Liu, Denfeng ^a,b   Ren, Diya ^a,c   Farnan, Dell ^a   Schenauer, Matthew R ^a  

^a Gilead Sciences   (United States)

^b MEDIMMUNE   (United States)

^c NONE   (United States)

Author keywords

biologic; biopharmaceutical; expression vector; heterogeneity; LC MS; mass spectrometry; monoclonal antibody; recombination; sequence variant; splicing

Indexed keywords

ARGININE CARBOXYPEPTIDASE; CARBOXYPEPTIDASE; GLYCINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHO-K1 CELL LINE; COLLISIONALLY ACTIVATED DISSOCIATION; DEGLYCOSYLATION; DNA RECOMBINATION; EXPRESSION VECTOR; HEAVY CHAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MASS SPECTROMETRY; MRNA EXPRESSION LEVEL; NONHUMAN; PEPTIDE MAPPING; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; PROTEOMICS; REVERSED PHASE LIQUID CHROMATOGRAPHY; RNA SPLICING; SPECTROPHOTOMETRY; STOICHIOMETRY; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; GENE VECTOR; GENETICS; HAMSTER; HUMAN; NUCLEOTIDE SEQUENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CHO CELLS; CRICETINAE; CRICETULUS; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G;

EID: 85056357553     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2018.1540254     Document Type: Article

References (46)

1. Harris RJ., Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol (Basel). 2005;122:117–127
2. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB., Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl. 2001;752:233–245
3. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci. 2008;97:2426–2447. doi:10.1002/jps.21180
4. Zhang Z. Large-scale identification and quantification of covalent modifications in therapeutic proteins. Anal Chem. 2009;81:8354–8364. doi:10.1021/ac901193n
5. Robinson NE, Robinson ZW, Robinson BR, Robinson AL, Robinson JA, Robinson ML, Robinson AB. Structure‐dependent nonenzymatic deamidation of glutaminyl and asparaginyl pentapeptides. J Pept Res. 2004;63:426–436. doi:10.1111/j.1399-3011.2004.00151.x
6. Eakin CM, Miller A, Kerr J, Kung J, Wallace A. Assessing analytical methods to monitor isoAsp formation in monoclonal antibodies. Front Pharmacol. 2014;5:87. doi:10.3389/fphar.2014.00087
7. J.F.Sydow, Lipsmeier F, Larraillet V, Hilger M, Mautz B, Mølhøj M, Kuentzer J, Klostermann S, Schoch J, Voelger HR, et al. Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions. PLoS ONE. 2014;9
8. Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci. 2009;98:3509–3521. doi:10.1002/jps.21655
9. Yu XC, Joe K, Zhang Y, Adriano A, Wang Y, Gazzano-Santoro H, Keck RG, Deperalta G, Ling V. Accurate determination of succinimide degradation products using high fidelity trypsin digestion peptide map analysis. Anal Chem. 2011;83:5912–5919. doi:10.1021/ac200750u
10. Houde D, Kauppinen P, Mhatre R, Lyubarskaya Y. Determination of protein oxidation by mass spectrometry and method transfer to quality control. J Chromatogr. 2006;1123:189–198. doi:10.1016/j.chroma.2006.04.046
11. Amano M, Kobayashi N, Yabuta M, Uchiyama S, Fukui K. Detection of histidine oxidation in a monoclonal immunoglobulin gamma (IgG) 1 antibody. Anal Chem. 2014;86:7536–7543. doi:10.1021/ac501300m
12. Chumsae C, Gaza-Bulseco G, Sun J, Liu H. Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;850:285–294. doi:10.1016/j.jchromb.2006.11.050
13. M.Hensel, Steurer R, Fichtl J, Elger C, Wedekind F, Petzold A, Schlothauer T, Molhoj M, Reusch D, Bulau P, et al. Identification of potential sites for tryptophan oxidation in recombinant antibodies using tert-Butylhydroperoxide and Quantitative LC-MS. PLoS ONE. 2011;6
14. Liu H, Gaza-Bulseco G, Zhou L. Mass spectrometry analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody. J Am Soc Mass Spectrom. 2009;20:525–528. doi:10.1016/j.jasms.2008.11.011
15. Brady LJ, Martinez T, Balland A. Characterization of nonenzymatic glycation on a monoclonal antibody. Anal Chem. 2007;79:9403–9413. doi:10.1021/ac7017469
16. Goetze AM, Liu DY, Arroll T, Chu L, Flynn GC. Rates and impact of human antibody glycation in vivo. Glycobiology. 2012;22:221–234. doi:10.1093/glycob/cwr141
17. Quan C, Alcala E, Petkovska I, Matthews D, Canova-Davis E, Taticek R, Ma S. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior. Anal Biochem. 2008;373:179–191. doi:10.1016/j.ab.2007.09.027
18. Jefferis R. Glycosylation of Recombinant Antibody Therapeutics. Biotechnol Prog. 2005;21:11–16. doi:10.1021/bp040016j
19. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol. 2000;37:697–706
20. Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25:1325–1334. doi:10.1093/glycob/cwv065
21. Chelius D, Wimer ME, Bondarenko PV. Reversed-phase liquid chromatography in-line with negative ionization electrospray mass spectrometry for the characterization of the disulfide-linkages of an immunoglobulin gamma antibody. J Am Soc Mass Spectrom. 2006;17:1590–1598. doi:10.1016/j.jasms.2006.07.008
22. Dillon TM, Ricci M, Vezina C, Flynn GC, Liu Y, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit S, et al. Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass. J Biol Chem. 2008;283:16206–16215. doi:10.1074/jbc.M709988200
23. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential Alkylation, and LC−MS analysis. Anal Chem. 2010;82:5219–5226. doi:10.1021/ac100575n
24. Harris RJ. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr. 1995;705:129–134
25. Cai B, Pan H, Flynn GC. C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo. Biotechnol Bioeng. 2011;108:404–412. doi:10.1002/bit.22933
26. Huang Y, Fu J, Ludwig R, Tao L, Bongers J, Ma L, Yao M, Zhu M, Das T, Russell R. Identification and quantification of signal peptide variants in an IgG1 monoclonal antibody produced in mammalian cell lines. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1068-1069:193–200. doi:10.1016/j.jchromb.2017.08.046
27. Kotia RB, Raghani AR. Analysis of monoclonal antibody product heterogeneity resulting from alternate cleavage sites of signal peptide. Anal Biochem. 2010;399:190–195. doi:10.1016/j.ab.2010.01.008
28. Ambrogelly A, Liu YH, Li H, Mengisen S, Yao B, Xu W, Cannon-Carlson S. Characterization of antibody variants during process development: the tale of incomplete processing of N-terminal secretion peptide. MAbs. 2012;4:701–709. doi:10.4161/mabs.21614
29. Wen D, Vecchi MM, Gu S, Su L, Dolnikova J, Huang Y-M, Foley SF, Garber E, Pederson N, Meier W. Discovery and investigation of misincorporation of serine at asparagine positions in recombinant proteins expressed in Chinese Hamster ovary cells. J Biol Chem. 2009;284:32686–32694. doi:10.1074/jbc.M109.059360
30. Ren D, Zhang J, Pritchett R, Liu H, Kyauk J, Luo J, Amanullah A. Detection and identification of a serine to arginine sequence variant in a therapeutic monoclonal antibody. J Chromatogr B. 2011;879:2877–2884. doi:10.1016/j.jchromb.2011.08.015
31. Fu J, Bongers J, Tao L, Huang D, Ludwig R, Huang Y, Qian Y, Basch J, Goldstein J, Krishnan R, et al. Characterization and identification of alanine to serine sequence variants in an IgG4 monoclonal antibody produced in mammalian cell lines. J Chromatogr B. 2012;908:1–8. doi:10.1016/j.jchromb.2012.09.023
32. Huang Y, O’Mara B, Conover M, Ludwig R, Fu J, Tao L, Li ZJ, Rieble S, Grace MJ, Russell RJ. Glycine to glutamic acid misincorporation observed in a recombinant protein expressed by Escherichia coli cells. Protein Sci. 2012;21:625–632. doi:10.1002/pro.2046
33. Feeney L, Carvalhal V, Yu CX, Chan B, Michels DA, Wang Y, Shen A, Ressl J, Dusel B, Laird MW. Eliminating tyrosine sequence variants in CHO cell lines producing recombinant monoclonal antibodies. Biotechnol Bioeng. 2013;110:1087–1097. doi:10.1002/bit.24759
34. Zhang Z, Shah B, Bondarenko PV. G/U and certain wobble position mismatches as possible main causes of amino acid misincorporations. Biochemistry. 2013;52:8165–8176. doi:10.1021/bi401002c
35. Harris RP, Kilby PM. Amino acid misincorporation in recombinant biopharmaceutical products. Curr Opin Biotechnol. 2014;30:45–50. doi:10.1016/j.copbio.2014.05.003
36. Wong HE, Huang CJ, Zhang Z. Amino acid misincorporation in recombinant proteins. Biotechnol Adv. 2018;36:168–181. doi:10.1016/j.biotechadv.2017.10.006
37. Brady LJ, Scott RA, Balland A. An optimized approach to the rapid assessment and detection of sequence variants in recombinant protein products. Anal Bioanal Chem. 2015;407:3851–3860. doi:10.1007/s00216-015-8618-1
38. Guo D, Gao A, Michels DA, Feeney L, Eng M, Chan B, Laird MW, Zhang B, Yu XC, Joly J, et al. Mechanisms of unintended amino acid sequence changes in recombinant monoclonal antibodies expressed in Chinese Hamster Ovary (CHO) cells. Biotechnol Bioeng. 2010;107:163–171. doi:10.1002/bit.22780
39. A.Zeck, Regula J, Larraillet V, Mautz B, Popp O, Göpfert U, Wiegeshoff F, Vollertsen UE, Gorr IH, Koll H, et al. Low level sequence variant analysis of recombinant proteins: an optimized approach. PLoS ONE. 2012;7
40. Valisheva I, Harris RJ, Zhu-Shimoni J. A sensitive mutation screening method supporting cell line development for biotherapeutics. Anal Biochem. 2016;505:73–75. doi:10.1016/j.ab.2016.04.007
41. Boyd D, Ebrahimi A, Ronan S, Mickus B, Schenauer M, Wang J, Brown D, Ambrogelly A. Isolation and characterization of a monoclonal antibody containing an extra heavy-light chain Fab arm. MAbs. 2018;10:346–353. doi:10.1080/19420862.2018.1438795
42. Lian Z, Wu Q, Wang T. Identification and characterization of a −1 reading frameshift in the heavy chain constant region of an IgG1 recombinant monoclonal antibody produced in CHO cells. MAbs. 2016;8:358–370. doi:10.1080/19420862.2015.1116658
43. Scott RA, Rogers R, Balland A, Brady LJ. Rapid identification of an antibody DNA construct rearrangement sequence variant by mass spectrometry. mAbs. 2014;6:1453–1463. doi:10.4161/mabs.36222
44. Zhang T, Huang Y, Chamberlain S, Romeo T, Zhu-Shimoni J, Hewitt D, Zhu M, Katta V, Mauger B, Kao Y-H. Identification of a single base-pair mutation of TAA (Stop codon) –> GAA (Glu) that causes light chain extension in a CHO cell derived IgG1. MAbs. 2012;4:694–700. doi:10.4161/mabs.22232
45. Wan M, Shiau FY, Gordon W, Wang GY. Variant antibody identification by peptide mapping. Biotechnol Bioeng. 1999;62:485–488
46. Spahr CS, Daris ME, Graham KC, Soriano BD, Stevens JL, Shi SDH. Discovery, characterization, and remediation of a C-terminal Fc-extension in proteins expressed in CHO cells. mAbs. 2018;1–10. doi:10.1080/19420862.2018.1511197